The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.
 
Jae Hong Park
Consulting or Advisory Role - Juno Therapeutics
Research Funding - Juno Therapeutics
 
Isabelle Riviere
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Xiuyan Wang
No Relationships to Disclose
 
Brigitte Senechal
No Relationships to Disclose
 
Yvette Bernal
No Relationships to Disclose
 
Elizabeth Halton
No Relationships to Disclose
 
Claudia Diamonte
No Relationships to Disclose
 
Yongzeng Wang
No Relationships to Disclose
 
Renier J. Brentjens
Stock and Other Ownership Interests - JUNO Therapeutics
Consulting or Advisory Role - JUNO Therapeutics
Research Funding - JUNO Therapeutics
Patents, Royalties, Other Intellectual Property - Scientific Cofounder of JUNO therapeutics
 
Michel Sadelain
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Licensed patent to Juno Therapeutics.